학술논문
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
Document Type
Article
Author
Source
In: Blood . (Blood, 13 February 2014, 123(7):985-991)
Subject
Language
English
ISSN
15280020
00064971
00064971